Brian J. Tunquist, Ph.D.
Affiliations: | 2003 | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Area:
Pharmacology, Molecular Biology, Cell BiologyGoogle:
"Brian Tunquist"Parents
Sign in to add mentor| James L. Maller | grad student | 2003 | University of Colorado, Denver | |
| (Mechanism of metaphase arrest by cytostatic factor in vertebrate eggs.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hernández-García S, San-Segundo L, González-Méndez L, et al. (2017) The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. Haematologica |
| Ocio EM, Motlló C, Rodriguez-Otero P, et al. (2016) Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group Blood. 128: 4503-4503 |
| Whiting JL, Nygren PJ, Tunquist BJ, et al. (2015) Protein Kinase A Opposes the Phosphorylation-dependent Recruitment of Glycogen Synthase Kinase 3β to A-kinase Anchoring Protein 220. The Journal of Biological Chemistry. 290: 19445-57 |
| Hernández-García S, González-Méndez L, Misiewicz-Krzeminska I, et al. (2015) Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism Blood. 126: 5353-5353 |
| Hernández-García S, San-Segundo L, González-Méndez L, et al. (2015) Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma Blood. 126: 1801-1801 |
| Hernández-García S, San-Segundo L, González-Méndez L, et al. (2015) Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs Clinical Lymphoma Myeloma and Leukemia. 15: e213-e214 |
| Humphries MJ, Anderson D, Williams L, et al. (2013) ARRY-520 Combined With Pomalidomide Displays Enhanced Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma Blood. 122: 3167-3167 |
| Tunquist B, Brown K, Hingorani G, et al. (2012) Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM) Blood. 120: 1868-1868 |
| Logue JS, Whiting JL, Tunquist B, et al. (2011) AKAP220 protein organizes signaling elements that impact cell migration. The Journal of Biological Chemistry. 286: 39269-81 |
| Logue JS, Whiting JL, Tunquist B, et al. (2011) Anchored protein kinase A recruitment of active Rac GTPase. The Journal of Biological Chemistry. 286: 22113-21 |